Reorganization of Reporting Segments and Resource Allocation for the Research Support and Medical Businesses
First written in FY2018-Q1. 21 of 22 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「Our group has divided its iPS cell technology business into 2 segments, the “Research Support Business” and the “Medical Business,” and is promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as the earnings base and the latter as the growth business, has been reaffirmed. - FY2026-H1RestatedAnnual report
「Against this backdrop, our group has divided its iPS cell technology business into 2 segments, the “Research Support Business” and the “Medical Business,” and is promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, has been reaffirmed. - FY2025-H1RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as the short- to medium-term earnings base and the latter as the medium- to long-term growth business, has been reaffirmed. - FY2024-Q3RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, has been reaffirmed. - FY2024-Q2RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, has been reaffirmed. - FY2023-Q3RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term source of earnings and the latter as a medium- to long-term growth business, has been reaffirmed. - FY2023-Q1RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as the earnings pillar and the latter as the growth business, has been reaffirmed. - FY2022-Q1RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term source of earnings and the latter as a medium- to long-term growth business, has been reaffirmed. - FY2021RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as the earnings pillar and the latter as the growth business, has been reaffirmed. - FY2021-Q3RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term business and the latter as a medium- to long-term business, has been reaffirmed. - FY2021-Q2RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term business and the latter as a medium- to long-term business, has been reaffirmed. - FY2021-Q1RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as the earnings pillar and the latter as the growth business, has been reaffirmed. - FY2020RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term business and the latter as a medium- to long-term business, has been reaffirmed. - FY2020-Q3RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, has been reaffirmed. - FY2020-Q2RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, has been reaffirmed. - FY2020-Q1RestatedAnnual report
「We classify the business of using iPS cells for elucidating disease mechanisms and drug discovery research, as described above, as the “Research Support Business,” and regenerative medicine, as described below, as the “Medical Business.” We have divided these into 2 segments and are promoting them accordingly.」
The framework of operating the business in 2 segments, the Research Support Business and the Medical Business, with the former as a short- to medium-term business and the latter as a medium- to long-term business, has been reaffirmed. - FY2019-Q3RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
Even after the reorganisation of the reporting segments, the approach of allocating resources to the Research Support Business as the short- to medium-term pillar and the Medical Business as the medium- to long-term growth strategy has been reaffirmed. - FY2019-Q2RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
The approach of allocating resources to the Research Support Business as the short- to medium-term pillar and the Medical Business as the medium- to long-term growth strategy has been reaffirmed. - FY2019-Q1RestatedAnnual report
「Against this business backdrop, the Group is developing its research support business, which provides research reagents and drug discovery support services related to iPS cells, as a short- to medium-term business pillar. As a medium- to long-term growth strategy, it is actively investing in the medical business, which is expected to address a huge market, with the aim of becoming a market leader in this field.」
Even after the reorganisation of the reporting segments, the approach of allocating resources to the Research Support Business as the short- to medium-term pillar and the Medical Business as the medium- to long-term growth strategy has been reaffirmed. - FY2018RestatedAnnual report
「From the current consolidated fiscal year, our group reorganised its reporting segments into the “Research Support Business” and the “Medical Business” for the purpose of appropriately managing business progress and allocating resources.」
The segments were reorganised into the Research Support Business and the Medical Business, reaffirming the approach of allocating resources to the former as the short- to medium-term pillar and the latter as the medium- to long-term growth driver. - FY2018-Q3RestatedAnnual report
「Against this backdrop, from the first quarter of the current consolidated fiscal year, our group reorganised its reporting segments into the “Research Support Business” and the “Medical Business” for the purpose of appropriately managing business progress and allocating resources. We aim to become a market leader in this field by promoting the “Research Support Business,” which provides research reagents and drug discovery support services related to iPS cells as a short- to medium-term business pillar, and by actively investing in the “Medical Business,” which is expected to address a huge market as part of our medium- to long-term growth strategy.」
Based on the reorganisation of the reporting segments, the approach of allocating resources to the Research Support Business as the short- to medium-term pillar and the Medical Business as the medium- to long-term growth strategy has been reaffirmed. - FY2018-Q1First statedAnnual report
「For the purpose of appropriately managing business progress and allocating resources, “Research Reagents” and “Drug Discovery Support” will be combined into the “Research Support Business,” while “Regenerative Medicine” will be classified as the “Medical Business.” In addition, the former “Clinical Testing Business” segment will be integrated into the “Medical Business.”」
The former “iPS Cell Business” and “Clinical Testing Business” segments were reorganised into the “Research Support Business,” combining research reagents and drug discovery support, and the “Medical Business,” integrating regenerative medicine and clinical testing. The aim is to improve business progress management and resource allocation.